Ensuring Patient-Centered Care In Oncology Trials

By Todd Rudo, M.D. – Chief Medical Officer at Clario, Robert Kleiman, M.D., Ph.D. – Chief Science and Regulatory Advisor, Cardiology at Clario, and Kelly Dumais, Ph.D. – Director, eCOA Science and Consulting at Clario

<p>In the realm of oncology trials, a primary focal point in every developmental program is the assurance of safety and tolerability. Evaluating the risk profile of a drug holds paramount importance in determining whether the advantages of treatment outweigh the associated risks.</p>

<p>However, an equally crucial aspect is the consideration of the patient&#39;s perspective. It is imperative to gauge the quality of life during clinical trials by actively seeking patient feedback through patient-reported outcomes (PROs). This approach is vital as it provides insights into the firsthand experiences of patients undergoing innovative treatments. By integrating safety data with quality of life and efficacy data, we ensure that the drugs making their way to the market not only deliver optimal therapeutic benefits but also positively influence the overall well-being of the patients prescribed these therapies.</p>

<p>From centralized ECGs to patient-reported outcomes, teams will want to utilize this guide for optimizing assessments of drug safety and quality of life.</p>